XML 24 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Shareholders' (Deficit) Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Ordinary shares
Preferred shares
Additional paid-in capital
Additional paid-in capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated deficit
Accumulated deficit
Cumulative Effect, Period of Adoption, Adjustment
Accumulated other comprehensive loss
Beginning balance (in shares) at Dec. 31, 2020     58,396 488     (384,187)    
Beginning balance at Dec. 31, 2020 $ 162,266 $ (12,939) $ 583 $ 5 $ 566,916 $ (26,699)   $ 13,760 $ (21,051)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (77,329)           $ (77,329)    
Other comprehensive loss (2,889)               (2,889)
Exercise of stock options (in shares)     48            
Exercise of stock options 169   $ 1   168        
Vesting of restricted shares (in shares)     159            
Vesting of restricted shares 0   $ 2   (2)        
Employee share purchase plan share issuance (in shares)     17            
Employee share purchase plan share issuance 94       94        
Share-based compensation expense 8,872       8,872        
Ending balance (in shares) at Dec. 31, 2021     58,620 488          
Ending balance at Dec. 31, 2021 78,244   $ 586 $ 5 549,349   (447,756)   (23,940)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (137,464)           (137,464)    
Other comprehensive loss (2,401)               (2,401)
Change in fair value of October 2023 Notes conversion feature 5,508       5,508        
Issuance of common stock under at-the-market offering program, net of issuance costs (in shares)     3,588            
Issuance of common stock under at-the-market offering program, net of issuance costs 25,318   $ 36   25,282        
Amortization of deferred issuance costs $ (45)       (45)        
Exercise of stock options (in shares) 450   451            
Exercise of stock options $ 2,460   $ 4   2,456        
Vesting of restricted shares (in shares)     144            
Vesting of restricted shares 0   $ 1   (1)        
Employee share purchase plan share issuance (in shares)     75            
Employee share purchase plan share issuance 222   $ 1   221        
Share-based compensation expense 7,013       7,013        
Ending balance (in shares) at Dec. 31, 2022     62,878 488          
Ending balance at Dec. 31, 2022 $ (21,145)   $ 628 $ 5 $ 589,783   $ (585,220)   $ (26,341)